<DOC>
	<DOC>NCT01536145</DOC>
	<brief_summary>This study represents the first-in-human study for CP-751,871. The study aimed to define the safety, tolerability, and maximum tolerated dose of CP-751,871 in patients with multiple myeloma through a dose escalation design.</brief_summary>
	<brief_title>CP-751,871 Treatment For Patients With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Previously treated multiple myeloma with a quantifiable serum (M spike ≥ 1 g/dL) and/or urine (≥ 200 mg/24hr) paraprotein Adequate bone marrow, renal, liver and cardiac function Eastern Cooperative Oncology Group [ECOG] performance status less than or equal to 2 Prior allogeneic stem cell transplant (alloSCT) Myelosuppressive chemotherapy or immunotherapy within 3 weeks prior to treatment with CP751,871 Prior organ allograft Concurrent use of insulin, oral hypoglycemic medication, growth hormone (GH), or growth hormone inhibitors Female patients who are pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>IGF-1R inhibitor</keyword>
	<keyword>CP-751871</keyword>
	<keyword>multiple myeloma</keyword>
</DOC>